---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-022895"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T20:49:49.337828+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q2 2023 net loss widens to $5.93M ($0.22/sh); cash at $17.8M

## Summary
- Net loss for Q2 2023 was $5.93M ($0.22/sh) vs $2.24M ($0.18/sh) in Q2 2022.
- R&D expenses jumped to $4.72M from $1.31M YoY, driven by clinical trial and manufacturing costs.
- Cash and equivalents totaled $17.8M at June 30, 2023, down from $27.6M at Dec 31, 2022.
- Initiated Phase 2 trial of GEO-CM04S1 in CLL patients; Gedeptin Phase 1/2 interim data showed no DLTs.
- Expanded GEO-CM04S1 rights to include Mpox and smallpox; partnered with ABL for cGMP manufacturing.

## SEC filing metadata
- accession: 0001437749-23-022895
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774923022895/0001437749-23-022895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774923022895/govx20230809_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-022895
- JSON: https://secwatch.observer/filing/0001437749-23-022895.json
- Plain text: https://secwatch.observer/filing/0001437749-23-022895.txt

## Key facts
- Earnings Releases
  GeoVax Labs, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774923022895/0001437749-23-022895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.